2nd Quarter - Report

SQUIRE PATTON BOGGS for RANBAXY INC.

Firm
Client
Income
$160,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

P.L. 111-148, Patient Protection and Affordable Care; P.L. 111-152, Health Care and Education Reconciliation; H.R. 3200, America's Affordable Health Choices; S. 1796, America's Healthy Futures;

Foreign entity interest: Ranbaxy Labs Limited; interests are same as registrant.

LobbyistCovered position, as disclosed
JOHN JONAS —
ERIC RASMUSSEN SenCrapoLA04-07andDepPresSec03-02LegIntenHatch2000
MATTHEW TODD TUTEN RepMichaelBilirakis91-92;93-95;98-01
ANURAG VARMA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3200 (111th), S. 1796 (111th)

Pharmacy PHA

S. 369, Preserve Access to Affordable Generics; H.R. 759, FDA Globalization

Foreign entity interest: Ranbaxy Labs Limited - Interests are same as Registrant;

LobbyistCovered position, as disclosed
ERIC RASMUSSEN SenCrapoLA04-07andDepPresSec03-02LegIntenHatch2000
MATTHEW TODD TUTEN RepMichaelBilirakis91-92;93-95;98-01

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 369 (111th), H.R. 759 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.